Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
ConditionType 1 Diabetes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIndiana University
About this trial
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults ≥18 years of age
Clinical diagnosis of T1D
GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
Disqualifiers
No exclusion criteria other than those not meeting inclusion criteria above
Trial population
Adults with type 1 diabetes who have been prescribed an adjunctive medications (GLP-1RA or SGLTi) as a part of their clinical care by their health care providers.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Change in HbA1c by type of therapy
Change in HbA1c from baseline to over 1 year by those receiving GLP-1RA and SGLTi
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Indiana University
Lead sponsor
Jaeb Center for Health Research
Collaborator
Source ClinicalTrials.gov